Media coverage about Arsanis (NASDAQ:ASNS) has been trending somewhat positive this week, according to Accern. Accern rates the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Arsanis earned a coverage optimism score of 0.10 on Accern’s scale. Accern also gave news coverage about the company an impact score of 46.1984260076075 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Here are some of the news articles that may have impacted Accern’s analysis:
- Reviewing Arsanis (ASNS) & Its Rivals (americanbankingnews.com)
- Brokerages Anticipate Arsanis (ASNS) to Post -$1.24 EPS (americanbankingnews.com)
- Zacks Investment Research Upgrades Arsanis (ASNS) to Buy (americanbankingnews.com)
- Arsanis (ASNS) Receives Average Rating of “Buy” from Brokerages (americanbankingnews.com)
- Zacks Investment Research Downgrades Arsanis (ASNS) to Hold (americanbankingnews.com)
Several research firms recently commented on ASNS. Zacks Investment Research upgraded Arsanis from a “hold” rating to a “buy” rating and set a $29.00 target price on the stock in a research report on Thursday, March 22nd. Cantor Fitzgerald set a $26.00 target price on Arsanis and gave the company a “buy” rating in a research report on Thursday, March 15th. Finally, ValuEngine upgraded Arsanis from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. Arsanis currently has a consensus rating of “Buy” and an average target price of $25.25.
Arsanis (NASDAQ:ASNS) last issued its quarterly earnings results on Friday, March 9th. The company reported ($1.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by ($0.82). research analysts expect that Arsanis will post -4.57 earnings per share for the current fiscal year.
Arsanis, Inc, a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address serious infectious diseases. Its lead product candidate is ASN100, a first-in-class mAb therapeutic in Phase II clinical development for the prevention of staphylococcus aureus pneumonia.
Receive News & Ratings for Arsanis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arsanis and related companies with MarketBeat.com's FREE daily email newsletter.